

June 24, 2005

**RESOLUTIONS OF THE 93RD ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
SANTEN PHARMACEUTICAL CO., LTD.**

Dear Shareholder:

We are pleased to announce that the following matters were reported and resolved today at the 93rd Annual General Meeting of Shareholders of Santen Pharmaceutical Co., Ltd.

REPORTS:

The contents of the following items were reported:

1. Business Report, Consolidated Balance Sheet, Consolidated Income Statement, Non-Consolidated Balance Sheet and Non-Consolidated Income Statement for the 93rd Business Term (April 1, 2004 to March 31, 2005)
2. Independent Auditor's Report and Corporate Auditors' Report on the consolidated financial statements
3. Report on the buy-back of Company stock pursuant to the resolution of the Board of Directors as authorized by the Articles of Incorporation

RESOLUTIONS:

Item No. 1 Appropriation of Retained Earnings for the 93rd Business Term

The proposed appropriation of retained earnings was approved. The term-end dividends were resolved to be JPY30 per share, making the total dividends for the business term JPY50 per share including the interim dividends.

Item No. 2 Election of Eight (8) Directors

The proposal of this item was approved. Takakazu Morita, Masahiro Mita, Katsuhiro Waga, Akira Kurokawa, Kosei Furukawa, Ichiro Otokozawa, Isao Muramatsu and Noboru Kotani were elected and all assumed their offices.

Kosei Furukawa, Isao Muramatsu and Noboru Kotani are external Directors prescribed in Article 188, paragraph 2, item 7-2 of the Commercial Code of Japan.

Item No. 3 Issuance of Stock Acquisition Rights as Stock Options

The proposal of this item was approved. Maximum of 1,360 units of Stock Acquisition Rights (136,000 shares) will be issued to the Company's Directors and Corporate Officers as well as Directors of the Company's major overseas subsidiaries.

Yours very truly,

Takakazu Morita
President & CEO
SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome,
Higashiyodogawa-ku, Osaka

NOTICE

At the meeting of the Board of Directors held after the close of this Annual General Meeting of Shareholders, Takakazu Morita was elected as President and Representative Director and Masahiro Mita as Managing Director, and they assumed their offices. Additionally, Corporate Officers were elected and will assume their offices effective July 1, 2005.

Directors and Corporate Auditors	Corporate Officers (excluding those concurrently serving as Directors)
Takakazu Morita Member of the Board President and CEO	Toshiaki Nishihata, Ph.D. Senior Corporate Officer Head of R&D Division
Masahiro Mita, M.D., Ph.D. Managing Director Corporate and Regulatory Affairs	Kenji Iwamoto Corporate Officer Head of Asia Division
Katsuhiko Waga Member of the Board Corporate, Community & Environment Relations	Masamichi Sato Corporate Officer Head of Sales & Marketing Division - OTC Products
Akira Kurokawa Member of the Board Senior Corporate Officer Head of Sales & Marketing Division, Prescription Pharmaceuticals	Adrienne Graves, Ph.D. Corporate Officer President of Santen Inc.
Ichiro Otokozaawa Member of the Board Senior Corporate Officer Head of Corporate Development and Administration Division, and Europe and the US Operation	Jyrki Liljeroos Corporate Officer President of Santen Oy
Kosei Furukawa * Member of the Board	Sadatoshi Furukado Corporate Officer Head of Pharmaceuticals Sales Department
Isao Muramatsu * Member of the Board	Kenji Morishima Corporate Officer Head of Product Supply Division
Noboru Kotani * Member of the Board	
Shushi Sakamoto ** Standing Corporate Auditor	
Yukinori Mizumoto Standing Corporate Auditor	
Koji Hori ** Corporate Auditor	
Tadao Kagono ** Corporate Auditor	

* Outside Director ** External Corporate Auditor

Balance Sheets and Income Statements on Website

As from the 91st Business Term, the Company places its Balance Sheets and Income Statements on its Website in lieu of giving public notice of account settlement. URL of Santen Website:

<http://www.santen.co.jp/en/>